What changed: Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)

When this page itself was last checked or edited.

Relapsed or refractory peripheral T-cell lymphoma

Confirmatory Ro-CHOP trial negative.

First-line CD30+ peripheral T-cell lymphoma with CHP (ECHELON-2)

Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy

A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018.

Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.

Brentuximab-CHP improves OS over CHOP; mogamulizumab approved for MF/Sézary (MAVORIC).

Brentuximab vedotin produced far more objective responses lasting at least four months than methotrexate or bexarotene; approved in November 2017.

A milestone in how this cancer is treated.

Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 12.2 years later, when the FDA's table was read.

Relapsed/refractory peripheral T-cell lymphoma

Relapsed or refractory peripheral T-cell lymphoma

A milestone in how this cancer is treated.

Relapsed CCR4+ adult T-cell leukaemia/lymphoma; later PTCL/CTCL

Peripheral T-cell lymphoma after ≥1 therapy

Overall response 79 per cent and complete response 45 per cent after two cycles, one-year overall survival 55 per cent, with grade 4 neutropenia in 92 per cent.

A milestone in how this cancer is treated.

Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 17.0 years later, when the FDA's table was read.

Relapsed/refractory peripheral T-cell lymphoma

Cutaneous T-cell lymphoma after ≥1 systemic therapy

First drugs specifically for relapsed PTCL.

Complete response 40 against 25 per cent (p = 0.

Palliative treatment of skin manifestations of cutaneous T-cell lymphoma unresponsive to other therapy, by extracorporeal photopheresis

NPM-ALK identified by Morris et al.; ALK-positive ALCL becomes the good-prognosis PTCL.

A milestone in how this cancer is treated.